KIF21A, Polyclonal Antibody

Anti -KIF21A (Kinesin Family Member 21A)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 12; NC_000012.11 (39687030..39837192, complement). Location: 12q12

Polyclonal

IgG

Rabbit

Recognizes mouse KIF21A, Mr ~180kD. An unknown protein detected at Mr ~70kD was also competed by the immunizing peptide. Species Crossreactivity: rat and human.

Affinity Purified
Purified by Protein A affinity chromatography.

Supplied as a liquid in 0.1M Tris-glycine, pH 7.4, 0.15M sodium chloride, 0.05% sodium azide before the addition of glycerol to 30%.

May be stored at 4 degree C for short-term only. For long-term storage, store at -20 degree C. Aliquots are stable for at least 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Small volumes of anti-KIF21A antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Antibodies; Abs to Motor Proteins

Western Blot (WB)

Suitable for use in Western Blot.
Dilution: Western Blot: 1-2ug/ml detects KIF21A in a rat brain microsomal preparation. Rat brain microsomal preparation was resolved by electrophoresis, transferred to nitrocellulose and probed with K1760-01 (2ug/ml). Proteins were visualized using a goat anti-rabbit secondary antibody conjugated to HRP and a chemiluminescence detection system.

187,179 Da[Similar Products]

kinesin family member 21A

kinesin-like protein KIF21A; renal carcinoma antigen NY-REN-62

Kinesin-like protein KIF21A

KIAA1708; KIF2  [Similar Products]

KI21A_HUMAN

This gene encodes a member of the KIF4 subfamily of kinesin-like motor proteins. The encoded protein is characterized by an N-terminal motor domain a coiled-coil stalk domain and a C-terminal WD-40 repeat domain. This protein may be involved in microtubule dependent transport. Mutations in this gene are the cause of congenital fibrosis of extraocular muscles-1. Alternate splicing results in multiple transcript variants.

KIF21A: Microtubule-binding motor protein probably involved in neuronal axonal transport. In vitro, has a plus-end directed motor activity. Defects in KIF21A are a cause of congenital fibrosis of extraocular muscles type 1 (CFEOM1). CFEOM encompasses several different inherited strabismus syndromes characterized by congenital restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. CFEOM is characterized clinically by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. CFEOM1 individuals show an absence of the superior division of the oculomotor nerve (cranial nerve III) and corresponding oculomotor subnuclei. Belongs to the kinesin-like protein family. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Microtubule-binding; Motor

Chromosomal Location of Human Ortholog: 12q12

Cellular Component: microtubule; kinesin complex; cytoplasm

Molecular Function: protein binding; microtubule binding; ATPase activity; microtubule motor activity; ATP binding

Biological Process: metabolic process; microtubule-based movement

Disease: Fibrosis Of Extraocular Muscles, Congenital, 1

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.